Loading...
XNAS
ABVC
Market cap43mUSD
Jun 27, Last price  
2.59USD
1D
18.26%
1Q
201.16%
Jan 2017
29.50%
IPO
-99.97%
Name

ABVC Biopharma Inc

Chart & Performance

D1W1MN
P/E
—
P/S
288.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.55%
Rev. gr., 5y
85.41%
Revenues
152k
-84.28%
57,4940041,66825,092-271,71814,8603,1905,7147,78703,360323,1966,956701,719483,045355,797969,783152,430
Net income
-11m
L-35.54%
2,539-26,670-25,399-4,650,870-6,770,322-5,182,192-1,901,060-1,218,651-1,069,579-226,352-70-32,281-4,507,799-5,048,271-4,101,303-3,933,240-10,593,584-12,035,851-16,312,374-10,515,656
CFO
-4m
L-42.75%
-7,446-18,42724,454-2,692,980-2,335,947-1,555,950-1,047,235-1,593,182-915,124-37,7681,1683,360-3,474,707-1,683,497-630,195-3,134,526-4,563,919-7,597,719-7,398,391-4,235,845
Earnings
Aug 12, 2025

Profile

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
URL
https://abvcpharma.com/
IPO date
Nov 09, 2004
Employees
19
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑092015‑09
Income
Revenues
152
-84.28%
970
172.57%
Cost of revenue
8,369
16,084
Unusual Expense (Income)
NOPBT
(8,217)
(15,114)
NOPBT Margin
Operating Taxes
256
798
Tax Rate
NOPAT
(8,473)
(15,912)
Net income
(10,516)
-35.54%
(16,312)
35.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,050
3,664
BB yield
-20.88%
-185.14%
Debt
Debt current
1,871
2,263
Long-term debt
1,217
1,953
Deferred revenue
Other long-term liabilities
22
(372)
Net debt
420
374
Cash flow
Cash from operating activities
(4,236)
(7,398)
CAPEX
(21)
(120)
Cash from investing activities
(360)
(1,722)
Cash from financing activities
3,919
4,014
FCF
(13,793)
(13,097)
Balance
Cash
139
161
Long term investments
2,528
3,681
Excess cash
2,660
3,793
Stockholders' equity
(65,161)
(53,837)
Invested Capital
75,591
60,136
ROIC
ROCE
EV
Common stock shares outstanding
4,336
3,166
Price
1.16
85.60%
0.63
-81.56%
Market cap
5,029
154.13%
1,979
-76.70%
EV
5,192
2,870
EBITDA
(8,188)
(15,091)
EV/EBITDA
Interest
2,493
294
Interest/NOPBT